Study S002751

A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Daily Administrations of the GLP-1 Analogue ROSE-010 on Appetite and Food Intake in Overweight and Obese Subjects

ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT06621017
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 40
Start: 2024-09-26
Primary completion: 2025-02-27
Lead sponsor: Rose Pharma Inc
Conditions: Obesity; Overweight
Interventions: DRUG:ROSE-010 99 mcg; DRUG:Placebo; DRUG:ROSE-010 150 mcg
Results posted: TRUE
Individual participant data sharing: NO

Registered primary outcomes

Food Consumption [30 minutes]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.